




PHARMACEUTICAL 2023

BioXcel Therapeutics Inc.
Rank 314 of 446





RealRate

PHARMACEUTICAL 2023

BioXcel Therapeutics Inc. Rank 314 of 446



The relative strengths and weaknesses of BioXcel Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BioXcel Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 43% points. The greatest weakness of BioXcel Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 92% points.

The company's Economic Capital Ratio, given in the ranking table, is -20%, being 63% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	202,868
Cost of Goods Sold	20
Intangible Assets	0
Liabilities, Current	32,898
Liabilities, Non-Current	93,837
Other Assets	1,901
Other Compr. Net Income	0
Other Expenses	8,213
Other Liabilities	2,343
Other Net Income	2,101
Other Revenues	375
Property and Equipment	1,084
Research and Development	91,239
Selling, General and Administrative Expense	68,761

Output Variable	Value in 1000 USD
Assets	205,853
Liabilities	129,078
Expenses	168,233
Revenues	375
Stockholders Equity	76,775
Net Income	-165,757
Comprehensive Net Income	-165,757
Economic Capital Ratio	-20%